Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Eli Lilly's stock showed surprising stability, with minimal movement despite significant pipeline developments. The ...

Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

China trade talks wrap up, Berkshire’s potential railroad deal, oil prices spike, and more news to start your day.

DelveInsight's,“ Chronic Heart Failure Pipeline Insight, 2025 ” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic Heart Failure pipeline landscape. It covers ...

Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...

DelveInsight’s, “Sleep Apnea Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea ...

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

AI-led drug for chronic lung disease set to enter phase 3 clinical trials, though experts remain divided on AI's impact in ...

DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...